Privia Health Group’s (PRVA) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Privia Health Group (NASDAQ:PRVA) in a report published on Friday morning,Benzinga reports. They currently have a $30.00 price objective on the stock.

A number of other research firms also recently issued reports on PRVA. Macquarie initiated coverage on shares of Privia Health Group in a research note on Monday, December 16th. They issued an “outperform” rating and a $25.00 price target on the stock. Piper Sandler boosted their price target on shares of Privia Health Group from $25.00 to $40.00 and gave the company an “overweight” rating in a research note on Friday, February 28th. Canaccord Genuity Group boosted their price target on shares of Privia Health Group from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, February 28th. JMP Securities set a $29.00 target price on shares of Privia Health Group in a research note on Friday, February 28th. Finally, JPMorgan Chase & Co. upped their target price on shares of Privia Health Group from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Friday, November 29th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $26.67.

Privia Health Group Stock Performance

Privia Health Group stock opened at $23.34 on Friday. The company’s 50 day simple moving average is $23.65 and its 200-day simple moving average is $21.02. The company has a market capitalization of $2.81 billion, a price-to-earnings ratio of 233.42, a price-to-earnings-growth ratio of 3.47 and a beta of 0.85. Privia Health Group has a 1 year low of $15.92 and a 1 year high of $26.04.

Institutional Investors Weigh In On Privia Health Group

A number of large investors have recently modified their holdings of the company. Nordea Investment Management AB boosted its holdings in shares of Privia Health Group by 33.1% in the 4th quarter. Nordea Investment Management AB now owns 349,773 shares of the company’s stock valued at $6,953,000 after buying an additional 86,910 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Privia Health Group by 402.9% in the 3rd quarter. Victory Capital Management Inc. now owns 179,049 shares of the company’s stock valued at $3,260,000 after buying an additional 143,446 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of Privia Health Group by 1.3% in the 4th quarter. Rhumbline Advisers now owns 287,200 shares of the company’s stock valued at $5,615,000 after buying an additional 3,658 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Privia Health Group by 2.2% in the 3rd quarter. Franklin Resources Inc. now owns 1,300,240 shares of the company’s stock valued at $23,092,000 after buying an additional 28,480 shares in the last quarter. Finally, Barclays PLC boosted its holdings in shares of Privia Health Group by 240.3% in the 3rd quarter. Barclays PLC now owns 224,018 shares of the company’s stock valued at $4,079,000 after buying an additional 158,188 shares in the last quarter. 94.48% of the stock is owned by hedge funds and other institutional investors.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.